dr. wenham on rationale for novel immunotherapy combos in ovarian cancer
Published 3 years ago • 1.3K plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
3:47
rationale for immunotherapy in ovarian cancer
-
1:42
dr. triebel on the rationale for a novel immunotherapy combination in melanoma
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
2:03
dr. wenham on trials evaluating ip, iv, and dose-dense chemotherapy in ovarian cancer
-
1:18
dr. arend on the rationale of novel combinations in gynecologic cancer
-
7:40
i/o combination strategies in ovarian cancer
-
1:06
dr. santin on rationale for trastuzumab in uterine serous carcinoma
-
5:24
what is the rationale for novel combination therapies?
-
1:40
dr. moore on immunotherapy and parp combinations in brca-mutated ovarian cancer
-
1:14
dr. coleman on rationale for using veliparib and chemotherapy in ovarian cancer
-
3:22
novel combination strategies in recurrent ovarian cancer
-
13:58
novel therapies and combinations in ovarian cancer
-
1:44
dr. zamarin on priming strategies in ovarian cancer
-
1:40
dr. zamarin discusses ongoing work with immunotherapy in ovarian cancer
-
3:39
dr. robert wenham at sitc 2022: car t therapy with ovarian cancer.
-
2:38
assessing the role of parp inhibitors and immunotherapy in ovarian cancer
-
2:20
dr. matulonis discusses niraparib/pembrolizumab combo in platinum-resistant ovarian cancer
-
1:15
dr. monk on immunotherapy for gynecologic cancer